Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Week In Review: Fosun Pharma Plans $690 Million Deal To Privatize Henlius, Its Biologics Subsidiary By: TalkMarkets June 30, 2024 at 14:20 PM EDT Shanghai Henlius Biotech agreed to be a wholly owned subsidiary of Fosun in a $690 million deal that values the company at $1.7 billion. Meanwhile, Suzhou Ascentage Pharma filed to list in the US to support its portfolio of drugs. Read More >> Related Stocks: Ascentage Pharma Group Casi Pharmaceuticals Inc Coherus Bio Innovent Biologics Inc Novo Nordisk A/S ADR Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
Week In Review: Fosun Pharma Plans $690 Million Deal To Privatize Henlius, Its Biologics Subsidiary By: TalkMarkets June 30, 2024 at 14:20 PM EDT Shanghai Henlius Biotech agreed to be a wholly owned subsidiary of Fosun in a $690 million deal that values the company at $1.7 billion. Meanwhile, Suzhou Ascentage Pharma filed to list in the US to support its portfolio of drugs. Read More >> Related Stocks: Ascentage Pharma Group Casi Pharmaceuticals Inc Coherus Bio Innovent Biologics Inc Novo Nordisk A/S ADR